Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. It also develops ET-105, a lamotrigine for oral suspension; DS-300, a cysteine injection; DS-100, a dehydrated alcohol injection; ET-104, a zonisamide oral suspension; ET-101, a topiramate oral suspension; and ET-203, an ephedrine ready-to-use injection. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
IPO Year: 2018
Exchange: NASDAQ
Website: etonpharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/23/2025 | $17.00 → $33.00 | Buy | H.C. Wainwright |
| 1/10/2025 | $21.00 | Buy | B. Riley Securities |
| 1/6/2025 | $15.00 → $17.00 | Buy | H.C. Wainwright |
| 9/4/2024 | $9.00 | Buy | H.C. Wainwright |
| 5/6/2024 | $8.00 | Buy | Craig Hallum |
| 10/14/2021 | $10.00 | Buy | B. Riley Securities |
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
144 - Eton Pharmaceuticals, Inc. (0001710340) (Subject)
8-K - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
10-Q - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
8-K - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
8-K - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
DEF 14A - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
8-K - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
8-K - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
SCHEDULE 13G/A - Eton Pharmaceuticals, Inc. (0001710340) (Subject)
10-K - Eton Pharmaceuticals, Inc. (0001710340) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
H.C. Wainwright reiterated coverage of Eton Pharmaceuticals with a rating of Buy and set a new price target of $33.00 from $17.00 previously
B. Riley Securities initiated coverage of Eton Pharmaceuticals with a rating of Buy and set a new price target of $21.00
H.C. Wainwright reiterated coverage of Eton Pharmaceuticals with a rating of Buy and set a new price target of $17.00 from $15.00 previously
H.C. Wainwright resumed coverage of Eton Pharmaceuticals with a rating of Buy and set a new price target of $9.00
Craig Hallum initiated coverage of Eton Pharmaceuticals with a rating of Buy and set a new price target of $8.00
B. Riley Securities resumed coverage of Eton Pharmaceuticals with a rating of Buy and set a new price target of $10.00
HC Wainwright & Co. reiterated coverage of Eton Pharmaceuticals with a rating of Buy and set a new price target of $14.00 from $15.00 previously
Fastest customizable press release news feed in the world
IMPAVIDO® is the first and only FDA-approved oral therapy for visceral, cutaneous, and mucosal leishmaniasis caused by specific Leishmania speciesLeishmaniasis is a rare but potentially life-threatening parasitic disease that can cause severe skin lesions or systemic infection involving internal organsExclusive U.S. commercialization rights to IMPAVIDO® take effect September 26, 2026 DEER PARK, Ill., May 19, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced it has entered into a supply and distribution agreement for the Unit
Q1 2026 product sales of $24.3 million, representing 73% growth over Q1 2025Raising full year revenue guidance - now expect 2026 revenue to exceed $120 million, up from previous guidance of $110 millionQ1 2026 fully diluted GAAP EPS of $0.05, non-GAAP fully diluted EPS of $0.14, and Adjusted EBITDA of $5.7 millionReceived FDA approval for and launched DESMODA™Acquired and relaunched HEMANGEOL®Announced initiation of ET-700 clinical study, the Company's extended-release formulation of zinc acetateReceived FDA clearance to proceed on INCRELEX® label harmonization studyManagement to hold conference call today at 4:30pm ET DEER PARK, Ill., May 14, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals
DEER PARK, Ill., May 12, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that executive management will participate in three upcoming investor conferences as follows: The 26th Annual B. Riley Securities Investor ConferenceDate: Wednesday, May 20, 2026Location: The Ritz-Carlton, Marina Del Rey, California The 23rd Annual Craig-Hallum Institutional Investor ConferenceDate: Thursday, May 28, 2026Location: Depot Renaissance Hotel Minneapolis, Minnesota Jefferies Global Healthcare ConferenceDate: Thursday, June 4, 2026 at 9:
DEER PARK, Ill., May 04, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2026 financial results on Thursday, May 14, 2026. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). Participant Call Link:Click Here Webcast:Click Here In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@eton
HEMANGEOL is now available exclusively through Anovo Specialty Pharmacy to streamline access and therapy initiationEton has integrated full Eton Cares patient support, including $0 co-pay for eligible commercially insured patients and expanded patient assistance programsHEMANGEOL is the only FDA-approved treatment for infantile hemangioma, a pediatric rare disease that can be time-sensitive DEER PARK, Ill., May 01, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the relaunch of HEMANGEOL®. "We are excited to deliver anoth
DEER PARK, Ill., April 27, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the first patient has been dosed in a pilot clinical study assessing the efficacy of ET-700, the Company's proprietary, patent-pending formulation of extended-release zinc acetate under development for the treatment of Wilson disease. Topline study results are expected in the second half of 2026, and if positive, would lead to a pivotal clinical study in early 2027. "ET-700 has the potential to deliver a major advancement for patients with Wilson di
DEER PARK, Ill., April 16, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the appointment of Judith "Judy" M. Matthews as Executive Vice President, Accounting and Finance. Ms. Matthews will assume the role of Chief Financial Officer effective June 1, 2026. The Company's current Chief Financial Officer, James Gruber, will then step down as part of a planned succession. To ensure a seamless transition, Mr. Gruber will remain in his role through May 31, 2026, and will subsequently enter into a six-month consulting agreement
Q4 2025 product sales of $21.3 million, representing 83% growth over Q4 2024Q4 2025 basic GAAP EPS of $0.06, fully diluted GAAP EPS of $0.05, basic non-GAAP EPS of $0.21, fully diluted non-GAAP EPS of $0.19, and Adjusted EBITDA of $6.2 millionLaunched DESMODA™, the first and only FDA-approved desmopressin oral solutionLicensed U.S. rights to Orphan Drug HEMANGEOL®; expected to be accretive to 2026 earningsCompany expects full year 2026 revenue to exceed $110 million with an Adjusted EBITDA margin of over 30%Management to hold conference call today at 4:30pm ET DEER PARK, Ill., March 19, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (NASDAQ:ETON), an innovati
DEER PARK, Ill., March 03, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter and full year 2025 financial results on Thursday, March 19, 2026. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). Participant Call Link: Click Here Webcast: Click Here In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email
HEMANGEOL® is the only FDA-approved treatment for infantile hemangiomaHEMANGEOL will be commercialized by Eton beginning May 1stHEMANGEOL will be distributed through the company's Eton Cares™ patient support program, which includes a $0 co-pay initiative, to broaden patient access. DEER PARK, Ill., March 02, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced it has in-licensed U.S. commercialization rights to HEMANGEOL® oral solution from Pierre Fabre Medicament Sas ("Pierre Fabre"). HEMANGEOL is an Orphan Drug indicated for
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
3 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
4 - Eton Pharmaceuticals, Inc. (0001710340) (Issuer)
Live Leadership Updates
DEER PARK, Ill., April 16, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the appointment of Judith "Judy" M. Matthews as Executive Vice President, Accounting and Finance. Ms. Matthews will assume the role of Chief Financial Officer effective June 1, 2026. The Company's current Chief Financial Officer, James Gruber, will then step down as part of a planned succession. To ensure a seamless transition, Mr. Gruber will remain in his role through May 31, 2026, and will subsequently enter into a six-month consulting agreement
Ms. Erdogan-Trinkaus brings a wealth of commercial leadership and expertise in sales and marketing from her tenure at leading global pharmaceutical companies and across the broader health and wellness sector, including significant experience in the pediatric endocrinology specialty. DEER PARK, Ill., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the appointment of Ipek Erdogan-Trinkaus as Chief Commercial Officer (CCO). Ms. Erdogan-Trinkaus brings to the Company broad commercial experience in the pharmaceutical
DEER PARK, Ill., April 11, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the appointment of James Gruber as Chief Financial Officer, effective immediately. He succeeds Wilson Troutman, who is retiring. Mr. Troutman will remain with the company through the end of May to ensure a smooth transition. "We are pleased to welcome James to the Eton team. He brings a wealth of experience managing the finance and accounting activities for some of the most successful companies in the industry. We look forward to benefiting from his financial expertise as we
LONDON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the "Company" or "Small Pharma"), a neuropharmaceutical company focused on psychedelic-assisted therapies, announces that Mr. Paul Maier has been appointed as a non-executive independent director of the board of directors of the Company (the "Board"). He will hold office as an independent director until the next annual meeting of shareholders, or until his successor has been elected or appointed. Mr. Maier has also been appointed as a member of the Audit Committee and Corporate Governance and Nominating Committee and Chair of the Compensation Committee. Mr. Maier joins Small Pharma with over 30 years' ex
DEER PARK, Ill., March 17, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has appointed Jenn Adams to its board of directors effective March 17, 2021. Ms. Adams brings extensive commercial, operational, and leadership experience in the pharmaceutical industry. “We are pleased to have Jenn join our board. Her experience growing pharmaceutical companies and leading sales organizations will be valuable to Eton as we continue to launch products and grow our commercial organization,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. Ms. Adam
Live finance-specific insights
Q1 2026 product sales of $24.3 million, representing 73% growth over Q1 2025Raising full year revenue guidance - now expect 2026 revenue to exceed $120 million, up from previous guidance of $110 millionQ1 2026 fully diluted GAAP EPS of $0.05, non-GAAP fully diluted EPS of $0.14, and Adjusted EBITDA of $5.7 millionReceived FDA approval for and launched DESMODA™Acquired and relaunched HEMANGEOL®Announced initiation of ET-700 clinical study, the Company's extended-release formulation of zinc acetateReceived FDA clearance to proceed on INCRELEX® label harmonization studyManagement to hold conference call today at 4:30pm ET DEER PARK, Ill., May 14, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals
DEER PARK, Ill., May 04, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2026 financial results on Thursday, May 14, 2026. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). Participant Call Link:Click Here Webcast:Click Here In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@eton
Q4 2025 product sales of $21.3 million, representing 83% growth over Q4 2024Q4 2025 basic GAAP EPS of $0.06, fully diluted GAAP EPS of $0.05, basic non-GAAP EPS of $0.21, fully diluted non-GAAP EPS of $0.19, and Adjusted EBITDA of $6.2 millionLaunched DESMODA™, the first and only FDA-approved desmopressin oral solutionLicensed U.S. rights to Orphan Drug HEMANGEOL®; expected to be accretive to 2026 earningsCompany expects full year 2026 revenue to exceed $110 million with an Adjusted EBITDA margin of over 30%Management to hold conference call today at 4:30pm ET DEER PARK, Ill., March 19, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (NASDAQ:ETON), an innovati
DEER PARK, Ill., March 03, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter and full year 2025 financial results on Thursday, March 19, 2026. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). Participant Call Link: Click Here Webcast: Click Here In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email
Q3 2025 product sales of $22.5 million, representing 129% growth over Q3 2024 and 19th straight quarter of sequential product sales growthQ3 2025 basic and fully diluted GAAP EPS of $(0.07), non-GAAP fully diluted EPS of $0.04, and Adjusted EBITDA of $2.9 millionET-600 NDA accepted for review, assigned PDUFA date of February 25, 2026GALZIN® launch ahead of plan; exceeded previous year-end target of 200 active patientsHeld positive FDA meeting clarifying pathway to KHINDIVI™ label expansionSubmitted proposed clinical study to support INCRELEX® label expansionGenerated $12.0 million of cash from operations in the quarterManagement to hold conference call today at 4:30pm ET DEER PARK, Ill., No
DEER PARK, Ill., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). Participant Call Link:Click HereWebcast:Click Here In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@eto
Q2 2025 product sales of $18.9 million, representing 108% growth over Q2 2024 and the 18th straight quarter of sequential product sales growthQ2 2025 basic and fully diluted GAAP EPS of $(0.10), non-GAAP fully diluted EPS of $0.03, and Adjusted EBITDA of $3.1 millionLaunched KHINDIVI™ (hydrocortisone) Oral SolutionReached 100 active INCRELEX® patients, ahead of previous guidance of year endCompany projects reaching an annual revenue run rate of $80 million in Q3, one quarter ahead of previous guidanceManagement to hold conference call today at 4:30pm ET DEER PARK, Ill., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (NASDAQ:ETON), an innovative phar
DEER PARK, Ill., July 28, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). Dial In: (800) 715-9871 or (646) 307-1963; Conference ID: 5899895 Webcast: Click Here In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. In
Q1 2025 revenue of $17.3 million, with product sales of $14.0 million, representing 76% growth over Q1 2024 and the 17th straight quarter of sequential product sales growthQ1 2025 basic and fully diluted GAAP EPS of $(0.06), Non-GAAP fully diluted EPS of $0.07, and Adjusted EBITDA of $3.7 millionRelaunched pediatric endocrinology biologic INCRELEX® in the U.S. and out-licensed international rightsEstablished Wilson disease franchise with the acquisition and relaunch of GALZIN® (zinc acetate) capsules and the introduction of product candidate ET-700Announced positive pivotal clinical study results for ET-600 and submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration
DEER PARK, Ill., May 01, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2025 financial results on Tuesday, May 13, 2025. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). Dial In* (Audio Only) Click Here Webcast: Click Here In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can
This live feed shows all institutional transactions in real time.
SC 13G - Eton Pharmaceuticals, Inc. (0001710340) (Subject)
SC 13G/A - Eton Pharmaceuticals, Inc. (0001710340) (Subject)
SC 13D/A - Eton Pharmaceuticals, Inc. (0001710340) (Subject)
SC 13G/A - Eton Pharmaceuticals, Inc. (0001710340) (Subject)
SC 13G/A - Eton Pharmaceuticals, Inc. (0001710340) (Subject)
SC 13D/A - Eton Pharmaceuticals, Inc. (0001710340) (Subject)
SC 13G/A - Eton Pharmaceuticals, Inc. (0001710340) (Subject)
SC 13G/A - Eton Pharmaceuticals, Inc. (0001710340) (Subject)
SC 13G/A - Eton Pharmaceuticals, Inc. (0001710340) (Subject)